ShockWave Medical (SWAV)
(Real Time Quote from BATS)
$328.90 USD
+0.14 (0.04%)
Updated Apr 23, 2024 01:14 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
SWAV 328.90 +0.14(0.04%)
Will SWAV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SWAV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SWAV
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
SWAV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
Other News for SWAV
Baron Health Care Fund Q1 2024 Shareholder Letter
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
Johnson & Johnson (JNJ) Q1 Earnings: Slight Gains Amid Adjusted Forecasts
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024